Myeloma Minute: Precise vs. personal myeloma treatment
|
| INNOVATION | Latest Research
Precision Myeloma Guidance Is Grounded in Solid ResearchWhile it might be tempting to compare outcomes among fellow myeloma patients in your support group, individual patients are often very different. The best treatment guidance is based on the best myeloma research.
|
|
|
| INNOVATION | Clinical Trials
IMROZ Clinical Trial Sites Are Now Open in the U.S.Isatuximab, a CD38 monoclonal antibody, is in phase III clinical trials for relapsed and refractory multiple myeloma patients. One of the two clinical trials using this therapy—the IMROZ study—has now opened sites in the U.S. This IMROZ study is a phase III trial that compares isatuximab in combination with bortezomib (Velcade®), lenalidomide (Revlimid®), and dexamethasone (IsaVRd) to bortezomib, lenalidomide, and dexamethasone (VRd) in newly diagnosed myeloma patients who are not eligible for autologous stem cell transplant (ASCT). The three U.S. cities where the IMROZ trial is currently accruing patients are
For further information, contact Sanofi at 800-633-1610, ext. 1, then #.
|
|
|
| INSPIRATION | 5K Run/Walk
|
| EDUCATION | Oncology Nursing
|
Sixth Annual Miracles for Myeloma 5K Race/Walk |
Watch This Oncology Nursing Video |
|
The Sixth Annual Miracles for Myeloma 5K Race/Walk takes place on Saturday, September 22, 2018, beginning at 9:30 a.m. EST on a USATF-certified course in Oak Ridge Park, New Jersey. Check-in is from 8:00 to 9:15 a.m. that day, and registration ends on September 18 at midnight. Donations can be made until December, whether or not you are able to participate. Last year’s Miracles for Myeloma raised nearly $80,000 for myeloma research, funding a Senior Brian D. Novis Research Grant. Once again, we encourage you to help raise myeloma awareness and funds as we work toward a cure. |
This video is the second in a three-part series on myeloma nursing. It was recorded at the IMF Satellite Symposium at the May 2018 Oncology Nursing Society’s annual meeting. In this segment, Beth Faiman, PhD, RN, MSN, APRN-BC, AOCN (Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH) and Kevin Brigle, PhD, NP (Massey Cancer Center, Virginia Commonwealth University, Richmond, VA) discuss newly diagnosed multiple myeloma, bone health, renal health, minimal residual disease, survivorship care, relapsed myeloma, therapeutic options, and immunotherapy considerations. |
|
|
|
|
| EDUCATION | Seminar
Register NOW for the IMF Patient & Family Seminar in Los AngelesOn August 24-25, 2018, the IMF will host a Patient & Family Seminar at the Hilton in Universal City (555 Universal Hollywood Drive) in Los Angeles. Choose between two registration packages—either attend for a half-day on Friday, or attend both Friday’s session and another whole-day event on Saturday. This seminar will cover the latest myeloma treatments, information about stem cell transplant, managing bone disease, and other myeloma-related topics. We welcome you to meet other patients and family members who have perhaps gone through what you’re going through now. Together, we can learn, build community, and share our stories.
|
|
|
| INNOVATION | Latest Research
Listen to a Replay of the Best of ASCO/EHA/IMWG TeleconferenceIn case you missed it, listen to a replay of last week’s Best of ASCO/EHA/IMWG teleconference. In this narrated slide presentation, Dr. Dr. Brian G.M. Durie explains the new and exciting current trends in myeloma treatment and research culled from three major medical meetings held in June 2018 — the American Society of Clinical Oncology (ASCO), the European Hematology Association (EHA), and the International Myeloma Working Group Summit (IMWG).
|
|
|
| #ASKDRDURIE | Dr. Durie's Weekly Web Video Series
|
|
CLINICAL TRIALS |
EVENTS |
|
New isatuximab Clinical Trial: the IMROZ Study New isatuximab Clinical Trial: the IKEMA Study New ixazomib Clinical Trials: Learn How to Participate Join the conversation about myeloma on the Smart Patients Message Board |
August 24-25, 2018 September 8, 2018 September 15, 2018 September 22, 2018 September 22, 2018 September 22, 2018 October 12-13, 2018 |
Amgen, Celgene Corporation, Genentech, Janssen Oncology, and Takeda Oncology
and individuals like you who supported the IMF this year